- Home
- DNLI vs DBD Comparison
DNLI vs DBD Comparison
Compare DNLI & DBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNLI
- DBD
- Stock Information
- Founded
- DNLI 2013
- DBD 1859
- Country
- DNLI United States
- DBD United States
- Employees
- DNLI N/A
- DBD N/A
- Industry
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- DBD EDP Services
- Sector
- DNLI Health Care
- DBD Technology
- Exchange
- DNLI Nasdaq
- DBD Nasdaq
- Market Cap
- DNLI 2.2B
- DBD 2.1B
- IPO Year
- DNLI 2017
- DBD N/A
- Fundamental
- Price
- DNLI $14.93
- DBD $56.23
- Analyst Decision
- DNLI Strong Buy
- DBD Strong Buy
- Analyst Count
- DNLI 13
- DBD 3
- Target Price
- DNLI $32.64
- DBD $73.33
- AVG Volume (30 Days)
- DNLI 1.5M
- DBD 156.8K
- Earning Date
- DNLI 11-03-2025
- DBD 11-05-2025
- Dividend Yield
- DNLI N/A
- DBD N/A
- EPS Growth
- DNLI N/A
- DBD N/A
- EPS
- DNLI N/A
- DBD N/A
- Revenue
- DNLI N/A
- DBD $3,672,300,000.00
- Revenue This Year
- DNLI N/A
- DBD $3.09
- Revenue Next Year
- DNLI $94,232.03
- DBD $2.74
- P/E Ratio
- DNLI N/A
- DBD N/A
- Revenue Growth
- DNLI N/A
- DBD N/A
- 52 Week Low
- DNLI $10.57
- DBD $34.88
- 52 Week High
- DNLI $33.33
- DBD $63.46
- Technical
- Relative Strength Index (RSI)
- DNLI 42.86
- DBD 41.44
- Support Level
- DNLI $15.53
- DBD $56.94
- Resistance Level
- DNLI $17.02
- DBD $60.03
- Average True Range (ATR)
- DNLI 0.79
- DBD 1.63
- MACD
- DNLI -0.19
- DBD 0.03
- Stochastic Oscillator
- DNLI 0.71
- DBD 23.51
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.